中西医治疗帕金森病的研究进展
Research Progress on the Treatment of Parkinson Disease with Traditional Chinese Medicine and Western Medicine
DOI: 10.12677/tcm.2026.159490, PDF,   
作者: 王兴宇：成都中医药大学临床医学院，四川 成都；杨东东*：成都中医药大学附属医院神经内科，四川 成都
关键词: 帕金森病；中西医疗法；综述；Parkinson Disease； Traditional Chinese and Western Medical Treatment； Summary
摘要: 帕金森病(Parkinson Disease, PD)是全球第二大常见的神经系统变性疾病。据统计，全球约有1000万名PD患者，而我国患者数已逾400万，位居全球第一。该病临床表现为运动与非运动症状，前者包括静止性震颤、运动迟缓、肌强直等，后者表现为便秘、失眠、焦虑等，共同降低了患者生活质量。中医自古将本病归属“颤证”、“震颤病”等范畴，认为其病机以肝肾亏虚、痰瘀阻络、髓海失养为主。随着中西医理念的深入，中西医治疗PD的临床与基础研究日益增多，成为研究热点。文章对近年来相关研究进行系统梳理，以期为PD的治疗提供参考。
Abstract: Parkinson disease is the second most common neurodegenerative disorder worldwide. It is estimated that there are approximately 10 million PD patients globally, with over 4 million in China, ranking first in the world. The clinical manifestations of this disease include both motor and non-motor symptoms. The former includes resting tremor, bradykinesia, and rigidity, while the latter includes constipation, insomnia, and anxiety, all of which reduce the quality of life of patients. In traditional Chinese medicine, this disease has been classified under the categories of “tremor syndrome” and “tremor disease”, with the main pathogenesis attributed to liver and kidney deficiency, phlegm and blood stasis blocking the meridians, and deficiency of the marrow sea. With the deepening of the integration of traditional Chinese and Western medicine concepts, clinical and basic research on the treatment of PD with both approaches has been increasing, becoming a research hotspot. This article systematically reviews the relevant research in recent years, with the aim of providing references for the treatment of PD.
文章引用：王兴宇, 杨东东. 中西医治疗帕金森病的研究进展[J]. 中医学, 2026, 15(9): 104-112. https://doi.org/10.12677/tcm.2026.159490

参考文献

[1] Surmeier, D.J., Obeso, J.A. and Halliday, G.M. (2017) Selective Neuronal Vulnerability in Parkinson Disease. Nature Reviews Neuroscience, 18, 101-113.
https://doi.org/10.1038/nrn.2016.178
[2] Ye, H., Robak, L.A., Yu, M., Cykowski, M. and Shulman, J.M. (2023) Genetics and Pathogenesis of Parkinson’s Syndrome. Annual Review of Pathology: Mechanisms of Disease, 18, 95-121.
https://doi.org/10.1146/annurev-pathmechdis-031521-034145
[3] De Miranda, B.R., Goldman, S.M., Miller, G.W., Greenamyre, J.T. and Dorsey, E.R. (2022) Preventing Parkinson’s Disease: An Environmental Agenda. Journal of Parkinson’s Disease, 12, 45-68.
https://doi.org/10.3233/jpd-212922
[4] Wang, Q., Luo, Y., Ray Chaudhuri, K., Reynolds, R., Tan, E. and Pettersson, S. (2021) The Role of Gut Dysbiosis in Parkinson’s Disease: Mechanistic Insights and Therapeutic Options. Brain, 144, 2571-2593.
https://doi.org/10.1093/brain/awab156
[5] 张小琪, 周路. 帕金森病中医病机及针灸辨治探讨[J]. 四川中医, 2023, 41(7): 26-28.
[6] 帕金森病及运动并发症中西医结合协作网络建设专家组, 刘振国. 基层帕金森病中西医结合诊疗专家共识[J]. 南京中医药大学学报, 2026, 42(7): 1080-1093.
[7] 宋书婷, 韩辉, 马斌, 等. 地黄饮子治疗阴阳两虚型帕金森病临床疗效观察[J]. 世界最新医学信息文摘, 2019, 19(16): 155-156.
[8] 贾志卫, 王雪静, 张国贤, 等. 大定风珠汤加减联合西药治疗肝肾阴虚型帕金森病疗效及对脑神经递质的影响[J]. 现代中西医结合杂志, 2024, 33(21): 3013-3016+3054.
[9] 杨亚男. 镇肝熄风汤加减治疗帕金森病(阴虚风动型)的临床观察及对氧化应激的影响[D]: [硕士学位论文]. 济南: 山东中医药大学, 2025.
[10] 赵丽丽, 陈莹, 张硕, 等. 中西医结合治疗75例帕金森病临床疗效观察[J]. 中医临床研究, 2020, 12(19): 88-91.
[11] 赵亚伟, 张娇, 牛双月, 等. 基于数据挖掘分析帕金森病针灸选穴规律[J]. 现代中西医结合杂志, 2024, 33(7): 976-981.
[12] Yu, N., Sun, D., Ma, L., Han, Q., Song, R. and Wang, Y. (2025) Acupuncture for Parkinson’s Disease: A Narrative Review of Clinical Efficacy and Mechanistic Insights. Neuropsychiatric Disease and Treatment, 21, 1731-1750.
https://doi.org/10.2147/ndt.s532027
[13] Pereira, C.R., Criado, M.B., Machado, J., Pereira, C.T. and Santos, M.J. (2021) Acute Effects of Acupuncture in Balance and Gait of Parkinson Disease Patients—A Preliminary Study. Complementary Therapies in Clinical Practice, 45, Article ID: 101479.
https://doi.org/10.1016/j.ctcp.2021.101479
[14] Wang, S.S., Sun, J.Q., Feng, Q.Y., Li, B., Wang, X., Yuan, F. and Cui, Y.X. (2024) Effectiveness of Electroacupuncture for Skeletal Muscle Pain in Parkinson’s Disease: A Clinical Randomized Controlled Trial. Journal of Traditional Chinese Medicine, 44, 388-395.
[15] Li, Y., Leong, I., Fan, J., Yan, M., Liu, X., Lu, W., et al. (2023) Efficacy of Acupuncture for the Treatment of Parkinson’s Disease-Related Constipation (PDC): A Randomized Controlled Trial. Frontiers in Neuroscience, 17, Article ID: 1126080.
https://doi.org/10.3389/fnins.2023.1126080
[16] Gu, S., Yin, P., Yang, M., Shi, R., Li, Q., Liu, J., et al. (2025) Efficacy and Safety of Electroacupuncture on Insomnia in Parkinson’s Disease: A Multicentre, Randomized, Controlled Trial. Movement Disorders Clinical Practice, 12, 1589-1601.
https://doi.org/10.1002/mdc3.70139
[17] https://d.wanfangdata.com.cn/periodical/CiBQZXJpb2RpY2FsQ0hJU29scjkyMDI2MDcyNzAzMTgxMhINc3h6eTIwMTcwOTAxORoIN3QxZzdxcG8%3D
[18] 孙赫楠. 针药结合治疗帕金森病32例疗效观察[J]. 内蒙古中医药, 2014, 33(13): 10-11.
[19] Xu, Y., Cai, X., Qu, S., Zhang, J., Zhang, Z., Yao, Z., et al. (2020) Madopar Combined with Acupuncture Improves Motor and Non-Motor Symptoms in Parkinson’s Disease Patients: A Multicenter Randomized Controlled Trial. European Journal of Integrative Medicine, 34, Article ID: 101049.
https://doi.org/10.1016/j.eujim.2019.101049
[20] 黄建福, 刘建浩, 谭春凤, 等. 针灸配合八珍汤合天麻钩藤饮加减治疗气血两虚型帕金森病的临床研究[J]. 中国中医基础医学杂志, 2020, 26(8): 1134-1137.
[21] Li, K., Xu, S., Wang, R., Zou, X., Liu, H., Fan, C., et al. (2023) Electroacupuncture for Motor Dysfunction and Constipation in Patients with Parkinson’s Disease: A Randomised Controlled Multi-Centre Trial. eClinicalMedicine, 56, Article ID: 101814.
https://doi.org/10.1016/j.eclinm.2022.101814
[22] 刘拥军, 窦海燕, 李鹏, 等. 复方地黄颗粒联合奥匹卡朋对帕金森患者的神经功能及日常生活能力的影响[J]. 江西医药, 2023, 58(7): 856-859.
[23] 陈韶兰. 脑康颗粒治疗肝肾亏虚型帕金森共病不宁腿综合征的临床研究[D]: [硕士学位论文]. 广州: 广州中医药大学, 2024.
[24] 毛明宇, 刘宗瑜, 徐冰馨, 等. 止颤颗粒治疗肝肾不足型帕金森病效果及对肠道微环境的影响[J]. 世界临床药物, 2025, 46(6): 572-580.
[25] 徐淼. 滋阴熄风颗粒治疗阴虚风动型帕金森病的临床疗效观察[D]: [硕士学位论文]. 长春: 长春中医药大学, 2024.
[26] 陈诗雅, 李茜羽, 张楚天, 等. 苁蓉舒痉颗粒对帕金森病患者黑质代谢物影响随机对照研究[J]. 中国中西医结合杂志, 2024, 44(3): 296-302.
[27] Hauser, R.A., Espay, A.J., Ellenbogen, A.L., Fernandez, H.H., Isaacson, S.H., LeWitt, P.A., et al. (2023) IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical Trial. JAMA Neurology, 80, 1062-1069.
https://doi.org/10.1001/jamaneurol.2023.2679
[28] Soileau, M.J., Aldred, J., Budur, K., Fisseha, N., Fung, V.S., Jeong, A., et al. (2022) Safety and Efficacy of Continuous Subcutaneous Foslevodopa-Foscarbidopa in Patients with Advanced Parkinson’s Disease: A Randomised, Double-Blind, Active-Controlled, Phase 3 Trial. The Lancet Neurology, 21, 1099-1109.
https://doi.org/10.1016/s1474-4422(22)00400-8
[29] Aldred, J., Freire-Alvarez, E., Amelin, A.V., Antonini, A., Bergmans, B., Bergquist, F., et al. (2023) Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results from a 12-Month, Single-Arm, Open-Label, Phase 3 Study. Neurology and Therapy, 12, 1937-1958.
https://doi.org/10.1007/s40120-023-00533-1
[30] Pahwa, R., Moro, E., Espay, A.J., Evans, A., Saint-Hilaire, M., Torres-Russotto, D., et al. (2026) Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical Trial. JAMA Neurology, 83, 452-460.
https://doi.org/10.1001/jamaneurol.2026.0590
[31] Fernandez, H.H., Bhatia, P., Cloud, L., Fietzek, U.M., Matarazzo, M., Molho, E., et al. (2026) Safety, Tolerability, and Efficacy of Flexible-Dose Tavapadon for Parkinson’s Disease (TEMPO-2): A Phase 3, Randomised, Placebo-Controlled, Double-Blind Trial. The Lancet Neurology, 25, 721-730.
https://doi.org/10.1016/s1474-4422(26)00215-2
[32] Fernandez, H.H., Isaacson, S.H., Hauser, R.A., Agarwal, P., Ondo, W., Park, A., et al. (2026) Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical Trial. JAMA Neurology, 83, 442-451.
https://doi.org/10.1001/jamaneurol.2026.0577
[33] Oehrn, C.R., Cernera, S., Hammer, L.H., Shcherbakova, M., Yao, J., Hahn, A., et al. (2024) Chronic Adaptive Deep Brain Stimulation versus Conventional Stimulation in Parkinson’s Disease: A Blinded Randomized Feasibility Trial. Nature Medicine, 30, 3345-3356.
https://doi.org/10.1038/s41591-024-03196-z
[34] Dalvi, A., Eisenberg, H.M., Wu, P., Zucker, L., Chang, W.C., Sarva, H., et al. (2026) Safety and Efficacy of Staged, Bilateral Magnetic Resonance-Guided Focused Ultrasound Pallidothalamic Tractotomy for Motor Complications of Parkinson’s Disease: A Prospective, Multicentre, Single-Arm Trial. The Lancet Neurology, 25, 654-663.
https://doi.org/10.1016/s1474-4422(26)00142-0
[35] Phielipp, N. and Henchcliffe, C. (2025) Investigational Gene Therapies for Parkinson’s Disease. CNS Drugs, 39, 725-737.
https://doi.org/10.1007/s40263-025-01203-6
[36] Sawamoto, N., Doi, D., Nakanishi, E., Sawamura, M., Kikuchi, T., Yamakado, H., et al. (2025) Phase I/II Trial of iPS-Cell-Derived Dopaminergic Cells for Parkinson’s Disease. Nature, 641, 971-977.
https://doi.org/10.1038/s41586-025-08700-0
[37] Tabar, V., Sarva, H., Lozano, A.M., Fasano, A., Kalia, S.K., Yu, K.K.H., et al. (2025) Phase I Trial of hES Cell-Derived Dopaminergic Neurons for Parkinson’s Disease. Nature, 641, 978-983.
https://doi.org/10.1038/s41586-025-08845-y
[38] Paul, G., Bjartmarz, H., Kirkeby, A., Nelander, J., Smith, R., Kayhanian, S., et al. (2026) Human Embryonic Stem Cell-Derived Dopaminergic Cells for Parkinson’s Disease: A Phase 1/2 Open-Label Trial. Nature Medicine.
https://doi.org/10.1038/s41591-026-04525-0
[39] Ghyselinck, J., Verstrepen, L., Moens, F., Van Den Abbeele, P., Bruggeman, A., Said, J., et al. (2021) Influence of Probiotic Bacteria on Gut Microbiota Composition and Gut Wall Function in an In-Vitro Model in Patients with Parkinson’s Disease. International Journal of Pharmaceutics: X, 3, Article ID: 100087.
https://doi.org/10.1016/j.ijpx.2021.100087
[40] Kuai, X., Yao, X., Xu, L., Zhou, Y., Zhang, L., Liu, Y., et al. (2021) Evaluation of Fecal Microbiota Transplantation in Parkinson’s Disease Patients with Constipation. Microbial Cell Factories, 20, Article No. 98.
https://doi.org/10.1186/s12934-021-01589-0
[41] Liu, J., Zhu, Y., Chen, B., Meng, Q., Hu, P., Chen, X., et al. (2025) Common and Specific Effects in Brain Oscillations and Motor Symptoms of tDCS and tACS in Parkinson’s Disease. Cell Reports Medicine, 6, Article ID: 102044.
https://doi.org/10.1016/j.xcrm.2025.102044
[42] Zhang, Z., Liu, D., Song, W., Li, J., Wang, X., Yin, P., et al. (2025) Multi‐Target Repetitive Transcranial Magnetic Stimulation Improves Freezing of Gait in Parkinson’s Disease: A Randomized Controlled Trial. CNS Neuroscience & Therapeutics, 31, e70582.
https://doi.org/10.1111/cns.70582
[43] van Kessel, S.P., Frye, A.K., El-Gendy, A.O., Castejon, M., Keshavarzian, A., van Dijk, G., et al. (2019) Gut Bacterial Tyrosine Decarboxylases Restrict Levels of Levodopa in the Treatment of Parkinson’s Disease. Nature Communications, 10, Article No. 310.
https://doi.org/10.1038/s41467-019-08294-y
[44] Maini Rekdal, V., Bess, E.N., Bisanz, J.E., Turnbaugh, P.J. and Balskus, E.P. (2019) Discovery and Inhibition of an Interspecies Gut Bacterial Pathway for Levodopa Metabolism. Science, 364, eaau6323.
https://doi.org/10.1126/science.aau6323
[45] Ai, P., Xu, S., Yuan, Y., Xu, Z., He, X., Mo, C., et al. (2025) Targeted Gut Microbiota Modulation Enhances Levodopa Bioavailability and Motor Recovery in MPTP Parkinson’s Disease Models. International Journal of Molecular Sciences, 26, Article No. 5282.
https://doi.org/10.3390/ijms26115282
[46] Chae, Y., Lee, H., Kim, H., Kim, C., Chang, D., Kim, K., et al. (2009) Parsing Brain Activity Associated with Acupuncture Treatment in Parkinson’s Diseases. Movement Disorders, 24, 1794-1802.
https://doi.org/10.1002/mds.22673
[47] Li, Z., Chen, J., Cheng, J., Huang, S., Hu, Y., Wu, Y., et al. (2018) Acupuncture Modulates the Cerebello-Thalamo-Cortical Circuit and Cognitive Brain Regions in Patients of Parkinson’s Disease with Tremor. Frontiers in Aging Neuroscience, 10, Article No. 206.
https://doi.org/10.3389/fnagi.2018.00206